Only in Titles

Search results for: Drug


#32746481   2020/08/03 To Up

Coronavirus Disease-2019 (COVID-19): An Updated Review.

The current outbreak of novel Coronavirus Disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major pandemic situation and a catastrophe for humans. COVID-19 is a severe infectious disease particularly of the respiratory system characterized by fatal complications such as severe acute respiratory distress syndrome (SARS), pneumonia, cardiac arrhythmia, kidney failure/ multiple organ failure and even death. Since its discovery, the SARS-CoV-2 has spread across 213 countries or territories, causing more than 8.5 million people with a rising death toll over 5.5 million people (as of June 2020, WHO). In fact, the current looming crisis of COVID-19 has become an increasingly serious concern to public health. It has affected lives of millions of people with severe impact on health systems and economies globally. Since there are no specific drugs and/or vaccines available so far, combating COVID-19 remains to be a major challenging task. Therefore, development of potential and effective treatment regimens (prophylactic/therapeutic) is urgently required which could resolve the issue. In this review, we summarize the current knowledge about the coronavirus, disease epidemiology, clinical manifestations and risk factors, replication of the virus, pathophysiology and host immune responses of SARS-CoV-2 infection. The therapeutic interventions and prophylactic measures along with precautionary measures are the frontline approaches that could be undertaken in order to control and prevent the spread of the deadly and highly contagious COVID-19 are also detailed herein.
Mithun Rudrapal, Shubham J Khairnar, Laxmikant B Borse, Anil G Jadhav

2358 related Products with: Coronavirus Disease-2019 (COVID-19): An Updated Review.

1 mg100 ug/vial100 100 µg200 1 mg200 200 50ug 1mg

Related Pathways


#32746480   2020/08/03 To Up

A Comprehensive Review on Physiological Effects of Curcumin.

Turmeric ( Linn) is an herbal medicine which is traditionally used as a spice, food colouring or flavouring agent and widely used for several diseases such as biliary disorders, cough, hepatic disorders, rheumatism, wound healing, sinusitis, diabetes, cardiac disorders and neurological disorder. It belongs to the family. Turmeric is a popular domicile remedy used in Indian food, is mainly a native of south-east Asia, is widely cultivated in India, Sri Lanka, Indonesia, China, Jamaica , Peru, Haiti and Taiwan and it is very less expensive. Curcumin is the main principle of turmeric. Curcumin has shown various biological properties pre-clinically and clinically. Curcumin is a highly pleiotropic molecule which can be modulators of various intracellular signalling pathways that maintain cell growth. It has been reported as anti-inflammatory, anti-angiogenic, antioxidant, wound healing, anti-cancer, anti-Alzheimer and anti-arthritis and possesses an excellent safety profile. All previous review articles on curcumin have collected the biological/pharmacological activities but this review article summarises the most interesting in vitro and in vivo studies of curcumin on most running diseases around the whole world.
Rabiya Ahsan, Md Arshad, Mohammad Khushtar, Mohd Afroz Ahmad, Mohammad Muazzam, Md Sohel Akhter, Gudiya Gupta, Mohd Muzahid

2599 related Products with: A Comprehensive Review on Physiological Effects of Curcumin.

100.00 ug 100ul2 Pieces/Box1 mg0.2 mg100.00 ug2.5 mg0.2 mg100ug100 µg100ug

Related Pathways


#32746479   2020/08/03 To Up

Analytical Method Development and Validation of UV-visible Spectrophotometric Method for the Estimation of Vildagliptin in Gastric Medium.

Vildagliptin is an antidiabetic agent, belongs to the dipeptidyl peptidase IV (DPP-4) inhibitors.
Beena Kumari, Aparna Khansili

1825 related Products with: Analytical Method Development and Validation of UV-visible Spectrophotometric Method for the Estimation of Vildagliptin in Gastric Medium.


Related Pathways

    No related Items

#32746478   2020/08/03 To Up

Materiovigilance: Concept, Structure and Emerging Perspective for Patient's Safety in India.

There has been an escalation in the number, diversity, and complexity of medical devices. Regulation of these devices has also advanced due to the requirement of better regulatory perspective induced due to elevation in the number of adverse events associated with medical devices. All over the globe, various measures are undertaken to provide better safety to the patients along with attempts to improve the standard of medical devices. The initial and ultimate objective of the concept happens to be unfailingly to ensure patient safety as well as impart required guidance for both manufacturers and adept authorities enabling them to superintend cases coherently and appropriately. Materiovigilance programme of India (MvPI) was launched by the Drug Controller General of India at the Indian Pharmacopoeia commission (IPC) in Ghaziabad in 2015. The main purpose of this initiative is to monitor adverse events associated with medical devices in order to generate safety data, create awareness among the various stakeholders, and prescribe best practices for patient safety. Whilst the reforms in regulations have proposed policies and designs to elucidate, consolidate and accelerate the processes involved in manufacturing and importing medical devices to India, they consistently carry their challenges and limitations. To eliminate such complications the guidelines and regulations are anticipated to be implemented appropriately with the efficacious conclusion. India has been evident in matching with advancements in the World Medical Device regulation scenario, the current review at hand takes upon the question of 'how successful has it been so far'?
Farazul Hoda, Rishabh Verma, Mawrah Arshad, Ali Nasir Siddiqui, Mohammad Ahmed Khan, Mohammad Akhtar, Abul Kalam Najmi

2536 related Products with: Materiovigilance: Concept, Structure and Emerging Perspective for Patient's Safety in India.

1 Set100 μg4 Membranes/Box

Related Pathways


#32746451   2020/08/03 To Up

Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro.

Breast cancer is the second leading cause of death among women globally. The existing treatment options for breast cancer are largely associated with severe toxicities, and lower efficacies. Therefore, there is an urgent need for the development of non-toxic effective drugs against breast cancer. For this purpose, drug repositioning strategy was used to evaluate the anti-cancer potential of a library of heterocyclic drugs. The major advantage of drug repurposing is that the pharmacokinetic, pharmacodynamic, and toxicity profiles of drugs are well documented. In the current study, we screened 97 drugs of different chemical classes, and among them aripiprazole, an antipsychotic drug, was found to be sufficiently active against breast cancer cell line MCF-7. Aripiprazole showed a cytotoxicity (IC50 = 12.1 ± 0.40 μM) to MCF-7 cells, comparable to the standard anticancer drug doxorubicin (IC50 = 1.25 ± 0.34 μM). Aripiprazole was also found to be active against other cancer cell lines, including MDA-MB-231 (IC50 = 19.83 ± 0.27 μM), AU565 (IC50 = 18.02 ± 0.44 μM), and BT-474 (IC50 = 36.42 ± 0.12 μM). Aripiprazole significantly inhibited the cell cycle progression at subG0G1 phase, and enhanced apoptosis in MCF-7 breast cancer cells. The drug was also able to significantly increase the nuclear condensation, and modulated the expression of certain genes involved in breast cancer, such as caspases 3, and 9, BAK-1, C-MYC, BCL2L1, BCL-10, and BCL-2. Further studies are needed to explore the effect of aripiprazole on intrinsic and extrinsic pathways of apoptosis in cancer cells.
Adnan Badran, Atia Tul-Wahab, Humaira Zafar, Nayab Mohammad, Rehan Imad, Mariam Ashfaq Khan, Elias Baydoun, M Iqbal Choudhary

2532 related Products with: Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro.

96 tests100 Plates100 assays100 assays24 tests

Related Pathways


#32746332   2020/07/03 To Up

Ultrashort Peptide Theranostic Nanoparticles by Microfluidic-Assisted Rapid Solvent Exchange.

Ultrashort peptides (USPs), composed of three to seven amino acids, can self-assemble into nanofibers in pure water. Here, using hydrodynamic focusing and a solvent exchange method on a microfluidic setup, we convert these nanofibers into globular nanoparticles with excellent dimensional control and polydispersity. Thanks to USP nanocarriers' structure, different drugs can be loaded. We used Curcumin as a model drug to evaluate the performance of USP nanocarriers as a novel drug delivery vehicle. These nanoparticles can efficiently cross the cell membrane and possess nonlinear optical properties. Therefore, we envisage USP nanoparticles as promising future theranostic nanocarriers.
Ming Ni, Guillaume Tresset, Ciprian Iliescu, Charlotte A E Hauser

1700 related Products with: Ultrashort Peptide Theranostic Nanoparticles by Microfluidic-Assisted Rapid Solvent Exchange.

200ul50 ug50 ug50 ug50 ug50 ug50 ug50 ug50 ug50 ug50 100 μg

Related Pathways


#32746293   2020/06/15 To Up

Dynamical features of a focal epileptogenic network model for stimulation-based control.

Much attention has been dedicated to clinical research of focal epilepsy, but the ability to derive a successful seizure control strategy based on unique dynamical features of the electroencephalogram is an unsolved problem. In this work, we introduce a basic model of spontaneous seizure dynamics and construct from it to a network model of focal-onset seizure dynamics. The full model is composed of coupled oscillators with scale-free network connectivity and a common slow variable. We find that global parameter changes and variation of the connectivity can drive the model from a quiescent state to recurrent seizures, and, eventually, to a permanent-seizure-state. Based on network synchronization features we design a stimulation scheme for the control of the fraction of nodes with strongest phase locking is proposed. Simulations lead to the identification of optimal stimuli for a given type of dynamics. Our results contribute to the development of a rational strategy for the nonsurgical treatment of drug-resistant epilepsy.
Liyuan Zhang, Qingyun Wang, Gerold Baier

2593 related Products with: Dynamical features of a focal epileptogenic network model for stimulation-based control.

100ug Lyophilized100μg250 mg 0.1 mg 100.00 ul

Related Pathways


#32746222   2020/07/24 To Up

Doppler Passive Acoustic Mapping.

In therapeutic ultrasound using microbubbles, it is essential to drive the microbubbles into the correct type of activity and the correct location to produce the desired biological response. Although passive acoustic mapping (PAM) is capable of locating where microbubble activities are generated, it is well known that microbubbles move rapidly within the ultrasound beam. We propose a technique that can image microbubble movement by estimating their velocities within the focal volume. Microbubbles embedded within a wall-less channel of a tissue-mimicking material were sonicated using 1-MHz focused ultrasound. The acoustic emissions generated by the microbubbles were captured with a linear array (L7-4). PAM with robust Capon beamforming was used to localize the microbubble acoustic emissions. We spectrally analyzed the time trace of each position and isolated the higher harmonics. Microbubble velocity maps were constructed from the position-dependent Doppler shifts at different time points during sonication. Microbubbles moved primarily away from the transducer at velocities on the order of 1 m/s due to primary acoustic radiation forces, producing a time-dependent velocity distribution. We detected microbubble motion both away and towards the receiving array, revealing the influence of acoustic radiation forces and fluid motion due to the ultrasound exposure. High-speed optical images confirmed the acoustically-measured microbubble velocities. Doppler PAM enables passive estimation of microbubble motion and may be useful in therapeutic applications, such as drug delivery across the blood-brain barrier, sonoporation, sonothrombolysis and drug release.
Antonios N Pouliopoulos, Cameron A B Smith, James H Bezer, Ahmed El Ghamrawy, Krit Sujarittam, Charlotte J Bouldin, Sophie V Morse, Meng-Xing Tang, James J Choi

1436 related Products with: Doppler Passive Acoustic Mapping.

Related Pathways


Error loading info... Pleas try again later.

#32746044   2020/06/29 To Up

Development of a Chewing Robot with Built-in Humanoid Jaws to Simulate Mastication to Quantify Robotic Agents Release from Chewing Gums Compared to Human Participants.

Medicated chewing gum has been recognised as a new advanced drug delivery method, with a promising future. Its potential has not yet been fully exploited because currently there is no gold standard for testing the release of agents from chewing gum in vitro. This study presents a novel humanoid chewing robot capable of closely replicating the human chewing motion in a closed environment, incorporating artificial saliva and allowing measurement of xylitol release from the gum. The release of xylitol from commercially available chewing gum was quantified following both in vitro and in vivo mastication. The chewing robot demonstrated a similar release rate of xylitol as human participants. The greatest release of xylitol occurred during the first 5 minutes of chewing and after 20 minutes of chewing only a low amount of xylitol remained in the gum bolus, irrespective of the chewing method used. Saliva and artificial saliva solutions respectively were collected after 5, 10, 15 and 20 minutes of continuous chewing and the amount of xylitol released from the chewing gum determined. Bioengineering has been implemented as the key engineering strategy to create an artificial oral environment that closely mimics that found in vivo. These results demonstrate the chewing robot with built-in humanoid jaws could provide opportunities for pharmaceutical companies to investigate and refine drug release from gum, with reduced patient exposure and reduced costs using this novel methodology.
Kazem Alemzadeh, Sian Bodfel Jones, Maria Davies, Nicola West

2920 related Products with: Development of a Chewing Robot with Built-in Humanoid Jaws to Simulate Mastication to Quantify Robotic Agents Release from Chewing Gums Compared to Human Participants.

25 100 μg100 1 kit100 μg50 0.1 mgOne 96-Well Strip Micropl10 1 kit(96 Wells)

Related Pathways